DRUG · Mapped RxNorm record
Durvalumab
Normalized identity: durvalumabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
NCT03820141
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Trastuzumab
Normalized identity: trastuzumabView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Pertuzumab
Normalized identity: pertuzumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedDurvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
DurvalumabDRUG · verified · RxNorm: durvalumab
TrastuzumabDRUG · verified · RxNorm: trastuzumab
PertuzumabDRUG · verified · RxNorm: pertuzumab
Sponsors & collaborators
The Methodist Hospital Research Institutelead sponsor
AstraZenecacollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03820141 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.